K
Kairos Pharma, LTD.
KAPACIK 0001962011NYSEEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-5.45M
Total Assets
$6.54M
Equity
$6.34M
Shares Out
21.41M
Op. Cash Flow
$-3.44M
Business
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company developing therapeutics designed to overcome immune suppression and drug resistance in cancer. It develops antibodies, small molecules, and activated T‑cell therapies—principally KROS 101, 102, 201, 301, 401 and Enviro agents ENV 105 and ENV 205—targeting checkpoints, tumor microenvironment, and mitochondrial DNA. Its operations include Kairos-developed immuno-oncology programs and its Enviro Therapeutics subsidiary that holds licensed technologies and drug candidates. Kairos advances candidates through investigator‑initiated and company trials at academic centers and through licensing and strategic partnerships across U.S. and select international jurisdictions.
Summary from filing dated 2025-04-15
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Revenues | — | — | — | |
| Research and development | 2 | 414,000 | 82,000 | |
| General and administrative | 3 | 2 | 2 | |
| Total operating expenses | 6 | 2 | 2 | |
| Loss from operations | −6 | −2 | −2 | |
| Interest expense | — | −35,000 | −42,000 | |
| Debt discount amortization | — | −154,000 | −56,000 | |
| Financing costs | — | −670,000 | — | |
| Gain on settlement of accounts payable | — | 599,000 | — | |
| Interest income | 125,000 | — | — | |
| Total other income (expenses) | 125,000 | −260,000 | −98,000 | |
| NET LOSS | −5 | −3 | −2 | |
| BASIC LOSS PER COMMON SHARE | −0.3 | −0.23 | −0.17 | |
| DILUTED LOSS PER COMMON SHARE | −0.3 | −0.23 | −0.17 | |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC | 18 | 11 | 10 | |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING DILUTED | 18 | 11 | 10 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 1 | — | — | |
| Vendor advances, net | 845,000 | 3 | — | — | |
| Prepaid expenses and other current assets | 51,000 | 38,000 | 8,000 | — | |
| Total Current Assets | 5 | 4 | 101,000 | — | |
| Deferred offering costs | 1 | 1 | 482,000 | — | |
| Intangible assets, net | 62,000 | 222,000 | 382,000 | — | |
| Total Other Assets | 1 | 2 | 864,000 | — | |
| TOTAL ASSETS | 7 | 6 | 965,000 | — | |
| Accounts payable and accrued expenses | 199,000 | 992,000 | 2 | — | |
| Total Current Liabilities | 199,000 | 992,000 | 2 | — | |
| Commitments and contingencies | — | — | — | — | |
| Preferred stock, par value $0.001, 20,000,000 shares authorized; no shares issued and outstanding, respectively; | — | — | — | — | |
| Common stock, par value $0.001, 100,000,000 shares authorized; 20,821,353 and 13,736,597 shares issued and outstanding, respectively; | 21,000 | 14,000 | 11,000 | — | |
| Additional paid-in capital | 21 | 14 | 4 | — | |
| Accumulated deficit | −14 | −9 | −6 | — | |
| Total Shareholders Equity | 6 | 5 | −2 | −1 | |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | 7 | 6 | 965,000 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Amortization of intangible asset | 160,000 | 160,000 | 160,000 | |
| Amortization of vendor advances | 2 | — | — | |
| Fair value of vested restricted stock units | 482,000 | 218,000 | — | |
| Fair value of common shares issued in connection with the conversion of accounts payable | — | 670,000 | — | |
| Fair value of warrants issued in connection with convertible notes payable | — | 29,000 | — | |
| Vendor advances | — | −2 | — | |
| Prepaid expenses and other current assets | −13,000 | −30,000 | −8,000 | |
| Accounts payable and accrued expenses | −793,000 | 404,000 | 772,000 | |
| Net cash used in operating activities | −3 | −4 | 81,000 | |
| Proceeds from the sale and exercise of prefunded warrants | 3 | — | — | |
| Proceeds from the equity line of credit | 4 | — | — | |
| Proceeds from common stock issued for cash in connection with the closing of the initial public offering | — | 6 | — | |
| Proceeds from notes payable - officers | — | 142,000 | — | |
| Repayment of notes payable - officers | — | −142,000 | — | |
| Payment of deferred offering costs | — | −390,000 | −425,000 | |
| Net cash provided by financing activities | 7 | 5 | −425,000 | |
| Net increase in cash and cash equivalents | 3 | 1 | −344,000 | |
| Interest paid | — | 3,000 | — | |
| Taxes paid | — | — | — | |
| Common shares issued for deferred offering costs | 327,000 | 1 | — | |
| Common shares issued for vendor advances | 157,000 | 500,000 | — | |
| Reclassification of deferred offering costs to shareholders equity | 614,000 | 872,000 | — | |
| Conversion of convertible notes payable and accrued interest to shareholders equity | — | 884,000 | — | |
| Conversion of accounts payable to shareholders equity | — | 1 | — | |
| Conversion of amounts due to related parties to shareholders equity | — | 4,000 | — | |
| Issuance of convertible notes payable recorded as debt discount | — | 49,000 | 68,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro